Longeveron Inc. (LGVN)
After hours:
| Previous Close | 2.2800 |
| Open | 2.3100 |
| Bid | 2.3000 x 900 |
| Ask | 2.3600 x 900 |
| Day's Range | 2.2600 - 2.3400 |
| 52 Week Range | 2.1200 - 4.5790 |
| Volume | |
| Avg. Volume | 124,039 |
| Market Cap | 49.531M |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.15 |
GlobeNewswireIBN Coverage Initiated for Longeveron Inc.
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- via IBN – Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announced it has selected the corporate communications expertise of IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its investor communications. Longeveron’s research and therapies a
GlobeNewswireLong-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today an abstract highlighting long-term survival data from the Company’s ELPIS 1 trial of Lomecel-B™ for patients with hypoplastic left heart syndrome
- GlobeNewswire
Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13 ,
